Parkinson's Disease Clinical Trials in San Antonio

Showing 81-100 of 132 trials

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

NCT02871427

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

Lewy Body DementiaDementia With Lewy BodiesParkinson's Disease Dementia+2 more

Axovant Sciences Ltd.80 participantsStarted Oct 2016

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Boca Raton, Florida, United States +16 more locations

COMPLETEDPhase 4< 1 mile

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

NCT00489255

The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii. To determine the optimal duration for continuation of Tigan® following initiation of Apokyn® therapy iii. To assess the safety of Tigan® in combination with Apokyn® iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®

Parkinson's Disease

Ipsen117 participantsStarted May 2007

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • La Jolla, California, United States +24 more locations

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

Parkinson's Disease Trials in Other Cities

Efficacy of Voice Treatment for Parkinson's Disease

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

Pioglitazone in Early Parkinson's Disease

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

DNS-7801 vs. Placebo in Parkinson's Disease

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Remote Access to Care, Everywhere, for Parkinson Disease

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Caffeine as a Therapy for Parkinson's Disease

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Other Conditions in San Antonio